A key element in the proposed Minnesota Guidelines for formulary submissions is the requirement for claims assessment protocols. If a manufacturer makes claims, whether they are in terms of clinical effectiveness or cost-effectiveness, then the committee should be told how those claims are to be evaluated. In the absence, for example, of a registry that may serve as a platform, the manufacturer should provide details of the platform design and implementation.
Dr Paul C Langley, Director, Maimon Research, has proposed ‘management platforms’ in three disease or product areas. These are similar to registries, but are designed to be implemented at the practice level to provide feedback in real time to the treating physician. The management platforms are in: